
Anna McGlothlin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6740239/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 384, 1491-1502.	27.0	1,419
2	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	27.0	778
3	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	27.0	712
4	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1317.	7.4	671
5	The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired) Tj ETQq1 1	0.784314 3.2	rgBT <u>/</u> Overloc 245
6	Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes. JAMA Oncology, 2016, 2, 751.	7.1	243
7	Effect of Convalescent Plasma on Organ Support–Free Days in Critically III Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1690.	7.4	169
8	Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis. JAMA - Journal of the American Medical Association, 2021, 325, 742.	7.4	168
9	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically III Hospitalized Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 227.	7.4	89
10	Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1247.	7.4	83
11	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Medicine, 2021, 47, 867-886.	8.2	65
12	The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. Trials, 2019, 20, 197.	1.6	57
13	Sutureless versus conventional bioprostheses for aortic valve replacement in severe symptomatic aortic valve stenosis. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 920-932.	0.8	55
14	Comparison of methods for control allocation in multiple arm studies using response adaptive randomization. Clinical Trials, 2020, 17, 52-60.	1.6	33
15	Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials. Therapeutic Innovation and Regulatory Science, 2021, 55, 1145-1154.	1.6	31
16	Interpretation of Clinical Trials That Stopped Early. JAMA - Journal of the American Medical Association, 2016, 315, 1646.	7.4	29
17	Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 315-326.	2.3	25
18	Binary Regression with Misclassified Response and Covariate Subject to Measurement Error: a Bayesian Approach. Biometrical Journal, 2008, 50, 123-134.	1.0	18

ANNA MCGLOTHLIN

#	Article	IF	CITATIONS
19	Comparison of response adaptive randomization features in multiarm clinical trials with control. Pharmaceutical Statistics, 2020, 19, 602-612.	1.3	16
20	Update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol: statistical analysis plan for a prospective, multicenter, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. Trials, 2019, 20, 670.	1.6	7
21	Hypothermia for Patients Requiring Evacuation of Subdural Hematoma: A Multicenter Randomized Clinical Trial. Neurocritical Care, 2022, 36, 560-572.	2.4	7
22	The design of a Bayesian adaptive clinical trial of tranexamic acid in severely injured children. Trials, 2021, 22, 769.	1.6	6
23	In response: Letter on update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol. Trials, 2020, 21, 351.	1.6	1
24	Optimizing Sample Size Allocation and Power in a Bayesian Two-Stage Drop-the-Losers Design. American Statistician, 2021, 75, 66-75.	1.6	1
25	PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. Leukemia and Lymphoma, 0, , 1-16.	1.3	1